TITLE

Mucosal Immunization with Attenuated Salmonella enterica Serovar Typhi Expressing Protective Antigen of Anthrax Toxin (PA83) Primes Monkeys for Accelerated Serum Antibody Responses to Parenteral PA83 Vaccine

AUTHOR(S)
Galen, James E.; Chinchilla, Magaly; Pasetti, Marcela F.; Jin Yuan Wang; Licheng Zhao; Arciniega-Martinez, Ivonne; Silverman, David J.; Levine, Myron M.
PUB. DATE
February 2009
SOURCE
Journal of Infectious Diseases;2/1/2009, Vol. 198 Issue 3, p326
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Salmonella enterica serovar Typhi vaccine strain CVD 908-htrA was genetically engineered for stable plasmidbased expression of protective antigen of anthrax toxin (PA83) fused with the export protein ClyA (ClyA-PA83). The priming potential of CVD 908-htrA expressing ClyA-PA83 was assessed in 12 rhesus and 20 cynomolgus macaques that were immunized mucosally (i.e., intranasally) on days 0 and 14. A parenteral booster with purified PA83 plus alum was given to rhesus macaques on days 42 and 225; cynomolgus monkeys received a booster with either PA or licensed anthrax vaccine (BioThrax; Emergent Biosolutions) only one time, 3 months after priming. Monkeys primed with S. Typhi expressing ClyA-PA83 developed high levels of serum toxin-neutralization activity (TNA) antibodies (50% effective dose [ED50],>1.3 × 103), 7 days after receipt of the booster, whereas unprimed controls lacked serumTNA(ED50, 0). In nonhuman primates, the success of this anthrax vaccine strategy based on heterologous mucosal priming followed by a parenteral subunit vaccine booster paves the way for clinical trials.
ACCESSION #
36327985

 

Related Articles

  • A Study on Longevity of Immune Response after Vaccination with Salmonella Typhi Vi Conjugate Vaccine (PedatyphTM) in Children. CHINNASAMI, BALAJI; SADASIVAM, KANIMOZHI; VIVEKANANDHAN, ARAVINDHAN; ARUNACHALAM, PREMA; PASUPATHY, SEKAR // Journal of Clinical & Diagnostic Research;May2015, Vol. 9 Issue 5, p1 

    Background and Objectives: Owing to the limitations of the conventional polysaccharide vaccines, global efforts have been made to develop conjugated polysaccharide vaccines for typhoid. Duration of immune response induced by these vaccines is critical to define the efficacy and frequency of...

  • The Novel Oral Typhoid Vaccine M01ZH09 Is Well Tolerated and Highly Immunogenic in 2 Vaccine Presentations. Kirkpatrick, Beth D.; Tenney, Katherine M.; Larsson, Catherine J.; O'Neill, J. Patrick; Ventrone, Cassandra; Bentley, Matthew; Upton, Anthony; Hindle, Zoë; Fidler, Christine; Kutzko, Deborah; Holdridge, Regan; Lapointe, Casey; Hamlet, Sandra; Chatfield, Steven N. // Journal of Infectious Diseases;8/1/2005, Vol. 192 Issue 3, p360 

    Background. M01ZH09 (Salmonella enterica serovar Typhi [Ty2 aroC- ssaV-] ZH9) is a live oral-dose typhoid vaccine candidate. M01ZH09 was rationally modified with 2 independently attenuating mutations, including a novel mutation in Salmonella pathogenicity island (SPI)-2. We demonstrate that...

  • Live Recombinant Salmonella Typhi Vaccines Constructed to Investigate the Role of rpoS in Eliciting Immunity to a Heterologous Antigen. Huoying Shi; Santander, Javier; Brenneman, Karen E.; Soo-Young Wanda; Shifeng Wang; Senechal, Patti; Wei Sun; Roland, Kenneth L.; Curtiss III, Roy // PLoS ONE;2010, Vol. 5 Issue 6, p1 

    We hypothesized that the immunogenicity of live Salmonella enterica serovar Typhi vaccines expressing heterologous antigens depends, at least in part, on its rpoS status. As part of our project to develop a recombinant attenuated S. Typhi vaccine (RASTyV) to prevent pneumococcal diseases in...

  • Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa. Brookes, Roger H.; Hill, Philip C.; Owiafe, Patrick K.; Ibanga, Hannah B.; Jeffries, David J.; Donkor, Simon A.; Fletcher, Helen A.; Hammond, Abdulrahman S.; Lienhardt, Christian; Adegbola, Richard A.; McShane, Helen; Hill, Adrian V. S. // PLoS ONE;2008, Vol. 3 Issue 8, p1 

    Background: Vaccination with a recombinant modified vaccinia Ankara expressing antigen 85A from Mycobacterium tuberculosis, MVA85A, induces high levels of cellular immune responses in UK volunteers. We assessed the safety and immunogenicity of this new vaccine in West African volunteers. Methods...

  • TAP: NOVEL TARGETS FOR CANCER VACCINE DEVELOPMENT.  // Pharma Magazine;Mar/Apr2011, Vol. 7 Issue 2, p32 

    The article focuses on the reduced expression of transporters associated with antigen presentation (TAP) as a promising approach for the development of cancer vaccines. It states that the decrease in major histocompatibility complex (MHC) Class I expression and the increased tumourigenicity are...

  • Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion. Bogers, Willy M.; Oostermeijer, Herman; Mooij, Petra; Koopman, Gerrit; Verschoor, Ernst J.; Davis, David; Ulmer, Jeffrey B.; Brito, Luis A.; Cu, Yen; Banerjee, Kaustuv; Otten, Gillis R.; Burke, Brian; Dey, Antu; Heeney, Jonathan L.; Shen, Xiaoying; Tomaras, Georgia D.; Labranche, Celia; Montefiori, David C.; Liao, Hua-Xin; Haynes, Barton // Journal of Infectious Diseases;Mar2015, Vol. 211 Issue 6, p947 

    Self-amplifying messenger RNA (mRNA) of positive-strand RNA viruses are effective vectors for in situ expression of vaccine antigens and have potential as a new vaccine technology platform well suited for global health applications. The SAM vaccine platform is based on a synthetic,...

  • Elicitation of Neutralizing Antibodies Directed against CD4-Induced Epitope(s) Using a CD4 Mimetic Cross-Linked to a HIV-1 Envelope Glycoprotein. Dey, Antu K.; Burke, Brian; Sun, Yide; Sirokman, Klara; Nandi, Avishek; Hartog, Karin; Lian, Ying; Geonnotti, Anthony R.; Montefiori, David; Franti, Michael; Martin, Gr�goire; Carfi, Andrea; Kessler, Pascal; Martin, Lo�c; Srivastava, Indresh K.; Barnett, Susan W. // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    The identification of HIV-1 envelope glycoprotein (Env) structures that can generate broadly neutralizing antibodies (BNAbs) is pivotal to the development of a successful vaccine against HIV-1 aimed at eliciting effective humoral immune responses. To that end, the production of novel Env...

  • Elicitation of Neutralizing Antibodies Directed against CD4-Induced Epitope(s) Using a CD4 Mimetic Cross-Linked to a HIV-1 Envelope Glycoprotein. Dey, Antu K.; Burke, Brian; Sun, Yide; Sirokman, Klara; Nandi, Avishek; Hartog, Karin; Lian, Ying; Geonnotti, Anthony R.; Montefiori, David; Franti, Michael; Martin, Grégoire; Carfi, Andrea; Kessler, Pascal; Martin, Loïc; Srivastava, Indresh K.; Barnett, Susan W. // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    The identification of HIV-1 envelope glycoprotein (Env) structures that can generate broadly neutralizing antibodies (BNAbs) is pivotal to the development of a successful vaccine against HIV-1 aimed at eliciting effective humoral immune responses. To that end, the production of novel Env...

  • Comparison of Immunogenicity in Balb/C Mice of Commercially Available Recombinant Hepatitis B Vaccines in Iran. Mahboubi, Arash; Shooshtari, Tahereh Hallaj; Fazeli, Mohammad Reza; Dinarvand, Rasoul; Samadi, Nasrin; Sharifzadeh, Mohammad; Ilka, Houshmand; Azadi, Saeed; Valadkhani, Mahboubeh // Journal of Medical Sciences;2008, Vol. 8 Issue 4, p415 

    In this study the immunogenicity of four commercially available hepatitis B recombinant vaccines in Iran was compared. The vaccines included both the well known brand of Engerix-B and three biosimilars of Heberbiovac HB, Euvax B and Hepavax-Gene. Vaccines were administered intra-peritoneally...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics